Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Im Cannabis Corp (IMCC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: IMCC (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Analysis of Past Performance
Type Stock | Historic Profit -16.77% | Avg. Invested days 44 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 4.69M USD | Price to earnings Ratio - | 1Y Target Price 8.22 |
Price to earnings Ratio - | 1Y Target Price 8.22 | ||
Volume (30-day avg) 7798 | Beta 1.98 | 52 Weeks Range 1.31 - 7.86 | Updated Date 04/3/2025 |
52 Weeks Range 1.31 - 7.86 | Updated Date 04/3/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.02 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Earnings Date
Report Date 2025-03-26 | When Before Market | Estimate -0.54 | Actual -0.22 |
Profitability
Profit Margin -19.59% | Operating Margin (TTM) -2.15% |
Management Effectiveness
Return on Assets (TTM) -9.95% | Return on Equity (TTM) -139.75% |
Valuation
Trailing PE - | Forward PE 16.31 | Enterprise Value 16746803 | Price to Sales(TTM) 0.09 |
Enterprise Value 16746803 | Price to Sales(TTM) 0.09 | ||
Enterprise Value to Revenue 0.44 | Enterprise Value to EBITDA -1.31 | Shares Outstanding 3085450 | Shares Floating 1601754 |
Shares Outstanding 3085450 | Shares Floating 1601754 | ||
Percent Insiders 43.88 | Percent Institutions 3.91 |
Analyst Ratings
Rating 3 | Target Price 8.22 | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Im Cannabis Corp
Company Overview
History and Background
iM Cannabis Corp. is not a publicly traded U.S. company. The company was founded in Israel in 2015, expanding into Canada and Germany. Details of its evolution are limited within the US market context.
Core Business Areas
- Cultivation: Cultivation of cannabis for medical and recreational use in licensed facilities. The company has cultivation sites in Israel and Canada.
- Distribution: Distribution of cannabis products through pharmacies and retail outlets.
- Retail: Retail sale of cannabis products in licensed stores. iM Cannabis has retail operations under the 'Focus Medical Herbs' brand in Israel.
- Pharmaceutical: Cannabis-based pharmaceutical product development and research.
Leadership and Structure
Details on iM Cannabis Corp's leadership team are readily available in corporate press releases and company web pages. The specific organizational structure is not publicly detailed.
Top Products and Market Share
Key Offerings
- Medical Cannabis Flower: Dried cannabis flower for medical use. Market share data for iM Cannabis specifically is not publicly available in the U.S. Competitors include Canopy Growth (CGC), Aurora Cannabis (ACB), and Tilray (TLRY).
- Cannabis Oils: Concentrated cannabis extracts in oil form for medical use. Market share data is unavailable. Competitors include Canopy Growth (CGC), Aurora Cannabis (ACB), and Tilray (TLRY).
- Cannabis Capsules: Cannabis extracts encapsulated for medical use. Market share data is not available. Competitors include Canopy Growth (CGC), Aurora Cannabis (ACB), and Tilray (TLRY).
Market Dynamics
Industry Overview
The cannabis industry is undergoing significant growth, facing evolving regulatory landscapes and increasing consumer acceptance. The U.S. market is fragmented, with both state-level and federal regulations impacting operations.
Positioning
iM Cannabis is attempting to position itself as a premium provider of medical cannabis products. Limited U.S. presence restricts their ability to compete with larger players.
Total Addressable Market (TAM)
The estimated TAM for the U.S. cannabis market is projected to reach billions of dollars annually. iM Cannabis has a limited presence within the US market, but the TAM is large.
Upturn SWOT Analysis
Strengths
- Established presence in Israel and Canada
- Focus on medical cannabis
- Cultivation capabilities
- Pharmaceutical product development
Weaknesses
- Limited U.S. presence
- Lack of brand recognition in the U.S.
- Financial constraints
- Uncertain regulatory environment in the U.S.
Opportunities
- Expansion into U.S. states with legal cannabis markets
- Partnerships with U.S. cannabis companies
- Development of innovative cannabis products
- Advocacy for cannabis legalization
Threats
- Federal prohibition of cannabis in the U.S.
- Intense competition from established cannabis companies
- Changing consumer preferences
- Regulatory hurdles and compliance costs
Competitors and Market Share
Key Competitors
- CGC
- ACB
- TLRY
- CRON
Competitive Landscape
iM Cannabis faces significant challenges in competing with larger, more established cannabis companies in the U.S. due to its limited U.S. presence and lack of brand recognition.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth analysis requires detailed financial data that is unavailable without more specific sources. Growth would be in the Israeli, Canadian and German markets.
Future Projections: Future growth projections are unavailable.
Recent Initiatives: Recent initiatives are generally found in company press releases. Without additional information, it is difficult to analyze recent inititiatives.
Summary
iM Cannabis Corp's US impact is limited. They face an uphill battle against established players. Their global medical focus and pharmaceutical product development could provide avenues for growth, but their US market entry will be tough. Regulatory hurdles and competition are significant challenges.
Similar Companies
ACB
Aurora Cannabis Inc
ACB
Aurora Cannabis Inc
CGC
Canopy Growth Corp
CGC
Canopy Growth Corp
CRON
Cronos Group Inc
CRON
Cronos Group Inc
TLRY
Tilray Inc
TLRY
Tilray Inc
Sources and Disclaimers
Data Sources:
- Company website, Industry reports, News articles
Disclaimers:
The information provided is for informational purposes only and should not be considered as financial advice. Market share data is estimated and may vary based on source.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Im Cannabis Corp
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2020-05-20 | CEO - | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees - | Website https://imcannabis.com |
Full time employees - | Website https://imcannabis.com | ||
IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel and Germany. It offers medical cannabis dried flowers; and full-spectrum, strain-specific cannabis extracts under the IMC, BLKMT, WAGNERS, and LOT420 brands. The company serves medical patients. IM Cannabis Corp. was founded in 2008 and is headquartered in Tel Aviv, Israel.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.